Abstract: Metastatic colorectal cancer (mCRC) is a clinical and molecular heterogeneous disease. Currently, for mCRC, extended rat sarcoma (RAS) testing is recommended in routine clinical practice before any treatment. RAS mutational status is significantly associated with the outcome of patients and strongly predictive for anti-EGFR-targeted therapy. However, specific treatments for RAS target are not yet available. Previous studies have shown that direct inhibition of RAS proteins has limited clinical benefits. Recently, a promising drug, AMG-510, which can directly inhibit KRAS G12C has been reported; however, it needs further confirmation. In the past few years, important advances have also been made in approaches designed to indirectly target RAS by inhibiting RAS effectors, multi-target combination strategies and immunotherapy. They are expected to be effective treatments for RAS target. This article summarizes the precision treatment of RAS-mutant mCRC.